Shu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shu Zhang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Heather M. O'Hagan
Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA
41 shared publications - Kenneth P. Nephew
Indiana University School of Medicine-Bloomington, Indiana University, Bloomington, USA
41 shared publications - Rena Y. Han
Indiana University School of Medicine 1 Bloomington, IN
24 shared publications - Riddhi Sood
Indiana University 2 Bloomington, IN
24 shared publications - Tara X. Metcalfe
Indiana University School of Medicine 1 Bloomington, IN
24 shared publications - Truc T. Vuong
Indiana University School of Medicine 1 Bloomington, IN
24 shared publications
Latest Publications
- Open Access
Targeting the MAT2A-SAM axis increases platinum sensitivity in ovarian cancer by impairing DNA repair and stemness
Metabolic and epigenetic reprogramming drives platinum resistance and recurrence in high-grade serous ovarian cancer (HGSC), presenting a critical clinical challenge. Acquired platinum resistance has been linked to altered DNA methylation, a process requiring S-adenosylmethionine (SAM), synthesized by methionine adenosyltransferase 2A (MAT2A) from methionine metabolism. However, how the MAT2A-SAM axis coordinates metabolic-epigenetic remodeling in HGSC remains unclear. We demonstrate that MAT2A-driven SAM synthesis is essential for platinum-induced DNA methylation dynamics and ovarian cancer stem cells (OCSCs) enrichment. High MAT2A expression correlates with poor progression-free survival in HGSC patients, while genetic knockdown or pharmacological inhibition of MAT2A increases cisplatin sensitivity in HGSC cells. Genome-wide DNA methylation profiling showed that cisplatin reshaped the methylome with prominent hypermethylation at promoter regions, which was reversed by MAT2A knockdown. Transcription factors predicted from differential methylation were enriched in platinum resistance, DNA repair, and stemness pathways. Mechanistically, disrupting MAT2A-SAM axis suppresses a novel SAMTOR-mTOR-S6K-FANCD2 signaling pathway. This blockade leads to the accumulation of R-loops, attenuates both homologous recombination (HR) and non-homologous end joining (NHEJ) repair pathways, and enhanced platinum-induced cell death. Furthermore, transcriptomic analysis of paired primary and recurrent HGSC tumors links MAT2A increase to elevated OCSC features during recurrence. Consistently, MAT2A inhibition prevents cisplatin-increased OCSC population and sphere-forming capacity in vitro, both of which are rescued by exogenous SAM supplementation. Together, our findings identify the MAT2A-SAM axis as a pivotal metabolic-epigenetic regulator of the DNA damage response and cancer stemness, establishing MAT2A inhibition as a therapeutic strategy to enhance platinum sensitivity in HGSC. Highlights: Cisplatin remodels the HGSC cell methylome with predominant promoter hypermethylation MAT2A-SAM is essential for platinum-induced methylome remodeling and OCSC enrichment MAT2A loss impairs activation of HR and NHEJ repair via mTOR-S6K-FANCD2 signaling MAT2A inhibition increases platinum sensitivity in both MTAP-proficient and -deficient HGSC cells tested
Open AccessTargeting the MAT2A-SAM axis increases platinum sensitivity in ovarian cancer by impairing DNA repair and stemness
Metabolic and epigenetic reprogramming drives platinum resistance and recurrence in high-grade serous ovarian cancer (HGSC), presenting a critical clinical challenge. Acquired platinum resistance has been linked to altered DNA methylation, a process requiring S-adenosylmethionine (SAM), synthesized by methionine adenosyltransferase 2A (MAT2A) from methionine metabolism. However, how the MAT2A-SAM axis coordinates metabolic-epigenetic remodeling in HGSC remains unclear. We demonstrate that MAT2A-driven SAM synthesis is essential for platinum-induced DNA methylation dynamics and ovarian cancer stem cells (OCSCs) enrichment. High MAT2A expression correlates with poor progression-free survival in HGSC patients, while genetic knockdown or pharmacological inhibition of MAT2A increases cisplatin sensitivity in HGSC cells. Genome-wide DNA methylation profiling showed that cisplatin reshaped the methylome with prominent hypermethylation at promoter regions, which was reversed by MAT2A knockdown. Transcription factors predicted from differential methylation were enriched in platinum resistance, DNA repair, and stemness pathways. Mechanistically, disrupting MAT2A-SAM axis suppresses a novel SAMTOR-mTOR-S6K-FANCD2 signaling pathway. This blockade leads to the accumulation of R-loops, attenuates both homologous recombination (HR) and non-homologous end joining (NHEJ) repair pathways, and enhanced platinum-induced cell death. Furthermore, transcriptomic analysis of paired primary and recurrent HGSC tumors links MAT2A increase to elevated OCSC features during recurrence. Consistently, MAT2A inhibition prevents cisplatin-increased OCSC population and sphere-forming capacity in vitro, both of which are rescued by exogenous SAM supplementation. Together, our findings identify the MAT2A-SAM axis as a pivotal metabolic-epigenetic regulator of the DNA damage response and cancer stemness, establishing MAT2A inhibition as a therapeutic strategy to enhance platinum sensitivity in HGSC. Highlights: Cisplatin remodels the HGSC cell methylome with predominant promoter hypermethylation MAT2A-SAM is essential for platinum-induced methylome remodeling and OCSC enrichment MAT2A loss impairs activation of HR and NHEJ repair via mTOR-S6K-FANCD2 signaling MAT2A inhibition increases platinum sensitivity in both MTAP-proficient and -deficient HGSC cells tested
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Supplementary Table S10 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Supplementary Table S10 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
ORA analysis with ChIPenrich on STAT3 and p65 CUT&RUN data.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
ORA analysis with ChIPenrich on STAT3 and p65 CUT&RUN data.
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Knocking down STAT3 or p65 did not affect the activity of the other.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Knocking down STAT3 or p65 did not affect the activity of the other.
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
DNMTi treatment prevents platinum-induced enrichment of OCSCs. A, ALDEFLUOR assays were performed on OVCAR3 cells treated with 100 nmol/L DAC for 72 hours, followed by 15 μmol/L platinum for the last 16 hours. Gates used to determine the %ALDH+ cells for one biological replicate are shown. B–E, Percent ALDH+ (%ALDH+) cells in the indicated cell lines, as determined by flow cytometry. Cells were untreated or treated with their respective IC50 doses of platinum (Pt) alone or in combination with 100 nmol/L DAC. Lines indicate mean ± SEM. Each dot represents a biological replicate (N = 3). F, Spheroid formation assay on OVCAR3 cells pretreated with platinum (7.5 μmol/L, 3 hours) alone or in combination with DAC (100 nmol/L, 72 hours) and then cultured for 7 days. Each point indicates a spheroid. All spheroids from three biological replicates (N = 3) are included. The graph shows the mean area ± SEM for all spheroids across three biological replicates. Significance is determined by one-way ANOVA and Tukey honestly significant difference test with **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Pt, platinum; UT, untreated.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
DNMTi treatment prevents platinum-induced enrichment of OCSCs. A, ALDEFLUOR assays were performed on OVCAR3 cells treated with 100 nmol/L DAC for 72 hours, followed by 15 μmol/L platinum for the last 16 hours. Gates used to determine the %ALDH+ cells for one biological replicate are shown. B–E, Percent ALDH+ (%ALDH+) cells in the indicated cell lines, as determined by flow cytometry. Cells were untreated or treated with their respective IC50 doses of platinum (Pt) alone or in combination with 100 nmol/L DAC. Lines indicate mean ± SEM. Each dot represents a biological replicate (N = 3). F, Spheroid formation assay on OVCAR3 cells pretreated with platinum (7.5 μmol/L, 3 hours) alone or in combination with DAC (100 nmol/L, 72 hours) and then cultured for 7 days. Each point indicates a spheroid. All spheroids from three biological replicates (N = 3) are included. The graph shows the mean area ± SEM for all spheroids across three biological replicates. Significance is determined by one-way ANOVA and Tukey honestly significant difference test with **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Pt, platinum; UT, untreated.
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
GSEA analysis using curated NH-KB and STAT3 target gene sets.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
GSEA analysis using curated NH-KB and STAT3 target gene sets.
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Platinum and DNMTi treatments differentially activate STAT3 and NF-κB in ovarian cancer cells. A, Heatmap of expression levels of genes curated from STAT3 and NF-κB target gene sets for each sample in the RNA-seq dataset. B–E, Western blot of whole-cell (WCE), nuclear, and chromatin lysates prepared from OVCAR3 and PEO1 cells treated with their respective IC50 doses of platinum for 16 hours, with or without 100 nmol/L DAC for 72 hours. The graphs show mean densitometric analysis ± SEM for pSTAT3 (N = 3) and p65 (N = 3) relative to the loading control (GAPDH for OVCAR3 WCE; total H3 for PEO1 WCE, as well as nuclear and chromatin lysates). Significance is determined by one-way ANOVA and the Tukey honestly significant difference test, with *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Pt, platinum; WCE, whole-cell extraction; UT, untreated.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Platinum and DNMTi treatments differentially activate STAT3 and NF-κB in ovarian cancer cells. A, Heatmap of expression levels of genes curated from STAT3 and NF-κB target gene sets for each sample in the RNA-seq dataset. B–E, Western blot of whole-cell (WCE), nuclear, and chromatin lysates prepared from OVCAR3 and PEO1 cells treated with their respective IC50 doses of platinum for 16 hours, with or without 100 nmol/L DAC for 72 hours. The graphs show mean densitometric analysis ± SEM for pSTAT3 (N = 3) and p65 (N = 3) relative to the loading control (GAPDH for OVCAR3 WCE; total H3 for PEO1 WCE, as well as nuclear and chromatin lysates). Significance is determined by one-way ANOVA and the Tukey honestly significant difference test, with *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Pt, platinum; WCE, whole-cell extraction; UT, untreated.
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
DNMTi induces greater cytokine secretion in OVCAR3 than platinum alone.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
DNMTi induces greater cytokine secretion in OVCAR3 than platinum alone.
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Data from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Platinum-based therapy is the standard first-line treatment for high-grade serous ovarian cancer (HGSC). However, most patients develop resistance and recurrence despite an initial response to therapy. Ovarian cancer stem cells (OCSC) are enriched in recurrent tumors and contribute to platinum resistance. These tumors also show promoter DNA hypermethylation, and DNA methyltransferase inhibitors (DNMTi) have been shown to restore sensitivity in platinum-resistant ovarian cancer cells. In this study, we demonstrated that combining DNMTi treamtent with platinum prevented the platinum-induced enrichment of OCSCs and identified nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription 3 (STAT3) signaling pathways as potential regulators of platinum-induced OCSC enrichment. STAT3 was active at baseline in ovarian cancer cells, and platinum treatment alone activated NF-κB while maintaining STAT3 activity. Platinum combined with DNMTi treatment decreased STAT3 activation, while still inducing NF-κB activation. Knockdown experiments demonstrated that the presence of both NF-κB and STAT3 was necessary for platinum-induced OCSC enrichment. Analysis of STAT3 and NF-κB subunit p65 CUT&RUN data showed increased binding in introns and intergenic regions in response to platinum. Additionally, DNMTi treatment enriched NF-κB binding at endogenous retroviruses, which correlated with changes in expression of nearby genes when DNMTi treatment was combined with platinum. We conclude that combining DNMTis with platinum modulates STAT3 and NF-κB activation and genomic binding, potentially influencing target gene expression and preventing platinum-induced enrichment of OCSCs.Significance:OCSCs promote relapse and chemoresistance in HGSC. We show that combining standard platinum-based therapy with DNMTi treatment prevents platinum-induced enrichment of OCSCs. Our findings support the use of DNMTis in combination with platinum as a strategy to reduce OCSC enrichment and platinum resistance in ovarian cancer.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
Platinum-based therapy is the standard first-line treatment for high-grade serous ovarian cancer (HGSC). However, most patients develop resistance and recurrence despite an initial response to therapy. Ovarian cancer stem cells (OCSC) are enriched in recurrent tumors and contribute to platinum resistance. These tumors also show promoter DNA hypermethylation, and DNA methyltransferase inhibitors (DNMTi) have been shown to restore sensitivity in platinum-resistant ovarian cancer cells. In this study, we demonstrated that combining DNMTi treamtent with platinum prevented the platinum-induced enrichment of OCSCs and identified nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription 3 (STAT3) signaling pathways as potential regulators of platinum-induced OCSC enrichment. STAT3 was active at baseline in ovarian cancer cells, and platinum treatment alone activated NF-κB while maintaining STAT3 activity. Platinum combined with DNMTi treatment decreased STAT3 activation, while still inducing NF-κB activation. Knockdown experiments demonstrated that the presence of both NF-κB and STAT3 was necessary for platinum-induced OCSC enrichment. Analysis of STAT3 and NF-κB subunit p65 CUT&RUN data showed increased binding in introns and intergenic regions in response to platinum. Additionally, DNMTi treatment enriched NF-κB binding at endogenous retroviruses, which correlated with changes in expression of nearby genes when DNMTi treatment was combined with platinum. We conclude that combining DNMTis with platinum modulates STAT3 and NF-κB activation and genomic binding, potentially influencing target gene expression and preventing platinum-induced enrichment of OCSCs.Significance:OCSCs promote relapse and chemoresistance in HGSC. We show that combining standard platinum-based therapy with DNMTi treatment prevents platinum-induced enrichment of OCSCs. Our findings support the use of DNMTis in combination with platinum as a strategy to reduce OCSC enrichment and platinum resistance in ovarian cancer.
- Open Access
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
DNMTi prevents platinum-induced enrichment of OCSCs.
- 20 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment
DNMTi prevents platinum-induced enrichment of OCSCs.